Vantictumab

Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.^[1]

Vantictumab

Monoclonal antibody
Type	?
Source	Human
Target	Frizzled receptor
Clinical data
Routes of administration	IV
ATC code	none
Identifiers
CAS Number	1345009-45-1
ChemSpider	none
UNII	88WBI2D80S
KEGG	D10410
Chemical and physical data
Formula	C6322H9722N1674O1988S46
Molar mass	142461.81 g·mol−1

This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.^[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.^[3] In April 2017, Bayer terminated its option to license vantictumab.^[4]

It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.^[5]

Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer^[5][6] and in 2020 for pancreatic cancer.^[7]